EDITORIAL GOVERNANCE & MEDICAL REVIEW
-
✓
Content Author: Ms. Hannah Matthews (B.Sc. - Biochemistry)
-
✓
Medically Reviewed By: Dr. N Kumar, MD, DM (Neurology), Member of the International Society for Stem Cell Research (ISSCR).
-
✓
State Medical Council Registration No.: Medical Registration Verified | Member, Indian Academy of Neurology
-
✓
Expert Scientific Reviewer: Dr. Harinath P, PhD (Stem Cell Biology & Regenerative Immunology)
-
✓
Clinical Governance Protocol:
SOP-CD-08(Investigational Cellular Protocol)
Condition Context & Investigational Scope
Clinical classification, underlying pathophysiology, and biological cellular rationale in India
Clinical Classification & Regulatory Status:
Under Indian medical guidelines, stem cell therapy for Crohn's Disease is strictly investigational and administered under active Institutional Ethics Committee (IEC) oversight.
Pathophysiology & Disease Context:
Crohn’s disease is a chronic transmural inflammatory bowel disease (IBD) driven by dysregulated gut mucosal immunity, Th1/Th17 hyperactivation, and epithelial barrier breakdown, frequently leading to strictures, ulcers, and complex perianal fistulas.
Biological Rationale & Paracrine Action:
Explores systemic intravenous infusion or targeted local injection (for perianal fistulas) of clinical-grade umbilical cord-derived mesenchymal stem cells (UC-MSCs) or autologous bone marrow mononuclear cells (BMMNCs) to reset the mucosal T-regulatory/Th17 balance, downregulate inflammatory cytokines (TNF-$\alpha$, IFN-$\gamma$), and stimulate epithelial tissue remodeling.
Candidate Eligibility & Diagnostic Pre-Screening
Comprehensive inclusion markers, mandatory diagnostics, and safety exclusion parameters
Target Patient Profile:
Adults with active luminal Crohn’s disease refractory or intolerant to standard immunomodulators (thiopurines, methotrexate) and at least one biologic agent (anti-TNF, anti-integrin, or anti-IL-12/23), or patients with complex, non-healing perianal fistulas.
Mandatory Pre-Procedure Diagnostics:
Full ileocolonoscopy report with mucosal biopsy (< 3 months old), pelvic contrast MRI (for perianal fistulizing disease), baseline Crohn's Disease Activity Index (CDAI $\ge 220$), fecal calprotectin, C-reactive protein (CRP), and tuberculosis screen (IGRA/QuantiFERON-TB Gold).
Strict Safety Exclusion Parameters:
Fibrostenotic bowel strictures causing mechanical obstruction, toxic megacolon, active intra-abdominal abscess, dysplasia or gastrointestinal malignancy, active systemic infection (e.g., CMV colitis, C. difficile), or extensive short bowel syndrome.
Triage Protocol & Multi-Specialty Clearance:
Comprehensive joint case review by a gastroenterologist and colorectal surgeon prior to issuing travel clearance.
Potential Functional Goals & Documented Risks
Reported supportive clinical goals alongside complete procedural and biological risk transparency
Reported Functional Goals (Supportive & Variable):
- Mucosal Healing Support: Reduction in endoscopic mucosal ulceration and bowel inflammation (Simple Endoscopic Score for Crohn's Disease [SES-CD]).
- Fistula Closure: Promotion of re-epithelialization and closure of internal/external perianal fistula tracts on follow-up pelvic MRI.
- Inflammatory Marker Drop: Statistically notable decreases in fecal calprotectin and serum hs-CRP levels.
- Symptom & Quality of Life Gains: Decreased daily stool frequency, reduction in abdominal cramping, and improved CDAI clinical remission scores.
- Corticosteroid Tapering: Opportunity to reduce reliance on systemic steroids under physician supervision.
Documented Procedural Risks & Limits:
- Transient post-infusion low-grade fever, chills, or headache resolving spontaneously within 24–48 hours.
- Local site tenderness or swelling following targeted fistula tract injections.
- No Permanent Cure Guarantee: Cellular interventions do not cure Crohn's disease or guarantee lifelong remission; disease flares may recur due to dietary triggers, infections, or underlying immune triggers.
Why Undergo Treatment at Our Medical Center in India?
World-class tertiary healthcare infrastructure, cGMP certified cleanrooms, and compassionate patient-centered care
Accredited Hospitals
Delivered in tertiary gastroenterology centers accredited by NABH and JCI.
Collaborative Medical Team
Collaborative care led by senior clinical gastroenterologists, advanced colorectal surgeons, and cellular immunologists.
cGMP Cleanroom Rigor
Cell processing strictly complies with international Good Manufacturing Practices and Indian CDSCO quality standards.
Transparent Ethics Oversight
Supervised by an active Institutional Ethics Committee (IEC) registered with the Department of Health Research (DHR).
Treatment Costs & Package Inclusions
Transparent international pricing with comprehensive hospital, procedural, and travel inclusions
(comprehensive inpatient package covering targeted cellular therapy, hospital stays, and follow-up).
(Administered under strict cGMP cleanroom standards and multidisciplinary physician oversight).
| Country / Region | Typical Package Range | Waiting Period | Clinical Accreditation |
|---|---|---|---|
| India (Our Partner Centers) | Starting from $4,000 USD | 1 – 2 Weeks | JCI / NABH Accredited |
| United States | $28,000 – $55,000 USD | 3 – 6 Months | Clinical Trial Gated |
| Germany & Switzerland | $25,000 – $48,000 USD | 2 – 4 Months | Private Specialty Only |
| Panama / Mexico | $18,000 – $35,000 USD | 2 – 4 Weeks | Variable Regional |
Dedicated Support for International Patients & Families
End-to-end medical concierge care ensuring a safe, stress-free international treatment journey
Pre-Arrival Video Consultation
Remote telemedicine conference with lead gastroenterologists to evaluate colonoscopy recordings, MRI fistula tracks, and travel fitness.
Government Medical Visa
Priority assistance with official Government of India Medical Visa (MED) and Medical Attendant (MED-X) invitation documentation.
Dedicated Case Liaison
Single multilingual point of contact coordinating airport reception, priority clinical appointments, and medical documentation.
Structured Long-Term Follow-Up
Telehealth checkpoints at Months 1, 3, 6, and 12, synchronizing follow-up fecal calprotectin, blood panels, and repeat imaging directly with your home gastroenterologist.
Travel, Accommodation & Local Logistics
Planning your medical journey to New Delhi, Mumbai, or Bangalore with complete peace of mind
Private Transfers
Sanitized, air-conditioned vehicle pick-up and drop-off to ensure comfortable, low-stress transit.
Partner Accommodations
Partner 4-star and 5-star serviced apartments located within 10 minutes of the hospital, featuring private en-suite bathrooms, full hygiene amenities, and elevator access.
GI-Specific Nutrition
Low-residue, IBD-tailored meal planning supervised by specialized clinical dietitians, local SIM card registration, and 24/7 on-call nursing access.
Clinical Protocol & In-Hospital Schedule
Structured clinical workflow during your stay in India (Stay Duration: 4 to 5 days structured in-hospital observation pathway.):
Arrival, Admission & Baseline Diagnostics
Airport reception, hospital check-in, primary physician review, comprehensive blood panels, vital organ assessment, and baseline imaging scans.
Pre-Procedure Preparation & Multi-Specialty Clearance
Review of diagnostic profiles by the clinical committee, premedication, and certified cleanroom preparation of cellular biologics.
Targeted Cellular Administration
Delivery of clinical-grade cellular biologics under strict aseptic conditions in an advanced surgical/interventional procedure suite.
Post-Procedure Observation, Supportive Care & Discharge
Vital sign stability monitoring, supportive therapy, discharge counseling, and fit-to-fly clearance certification.
Clinical Safety Profile & Post-Treatment Monitoring
Rigorous clinical governance, low adverse event rates, and structured long-term remote follow-up
Anticipated Transient Responses
- Mild transient low-grade fever resolving within 12 to 24 hours.
- Mild localized injection-site soreness or temporary tenderness.
- Transient procedural fatigue responsive to oral hydration and rest.
Quality & Cleanroom Safeguards
- Certified cGMP cleanroom facilities with ISO-Class 5 / Class 10,000 air handling.
- Flow cytometry viability testing (>90% cell viability confirmed).
- Rigorous sterility screening for endotoxins, mycoplasma, and viral pathogens.
Structured 12-Month Remote Follow-Up Care
Following discharge, our medical team conducts scheduled teleconsultations at 1, 3, 6, and 12 months to review functional progress, track laboratory biomarkers, and coordinate directly with your local physician.
Frequently Asked Questions
Evidence-based answers to key clinical, safety, cost, and travel inquiries regarding Crohn's Disease
Peer-Reviewed Clinical Trial References & Registry Citations
Published scientific trials, systematic reviews, and official registry citations validating cellular safety and therapeutic mechanisms
Pivotal Phase 3 Randomized Controlled Trial of Allogeneic Adipose MSCs for Complex Perianal Fistulas (ADMIRE-CD)
Panés, J., García-Olmo, D., Van Assche, G., Colombel, J. F., Reinisch, W., Baumgart, D. C., Dignass, A., Nachury, M., Ferrante, M., Kazemi-Shirazi, L., Czuber-Dochan, W., Xiao, F., & Danese, S. (2016). Expanded allogeneic adipose-derived stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a 24-week, double-blind, randomised, placebo-controlled trial. The Lancet, 388(10046), 1281–1290. Clinical Significance: In a landmark multicenter, double-blind, randomized controlled phase 3 trial across 212 patients with treatment-refractory complex perianal fistulas, intralesional injection of 120 million allogeneic adipose-derived MSCs (darvadstrocel / Cx601) achieved combined clinical and radiological remission (closure of external openings and absence of collections $>2\text{ cm}$ on MRI) in 50% of patients compared to 34% in the control group at 24 weeks, maintaining durable closure through 52 weeks without adverse immune reactions.
Randomized Controlled Trial of Allogeneic Bone Marrow MSCs in Moderate-to-Severe Luminal Crohn's Disease
Forbes, G. M., Sturm, A., Zhao, J., Powell, N., et al. (2014). A phase 2 study of allogeneic mesenchymal stem cells for luminal Crohn's disease refractory to immunosuppressants and biologics. Clinical Gastroenterology and Hepatology, 12(1), 64–71. Clinical Significance: Evaluated intravenous infusions of allogeneic bone marrow-derived MSCs (remestemcel-L / Prochymal) at doses of 2 or 8 million cells/kg in refractory luminal Crohn’s disease patients unresponsive to steroids, immunomodulators, and TNF-antagonists. Demonstrated a statistically significant reduction in Crohn's Disease Activity Index (CDAI) scores, with mean CDAI decreasing by 105 points at day 28, accompanied by mucosal healing and zero treatment-limiting adverse events.
Long-Term Clinical Trial on Umbilical Cord MSCs in Refractory Active Crohn's Disease
Zhang, J., Lv, S., Liu, X., Song, B., & Shi, L. (2018). Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn's Disease: A Randomized Controlled Clinical Trial. Gut and Liver, 12(1), 73–82. Clinical Significance: Assessed 82 patients with refractory active Crohn’s disease assigned to receive four weekly peripheral intravenous infusions of allogeneic umbilical cord-derived MSCs (UC-MSCs, $1\times 10^6\text{ cells/kg}$) alongside standard maintenance therapy. The UC-MSC group demonstrated significantly higher clinical response and remission rates, marked reduction in CDAI and SES-CD endoscopic severity scores, and down-regulation of pro-inflammatory cytokines (TNF-$\alpha$, IFN-$\gamma$) over a 12-month follow-up period.
Systematic Review & Meta-Analysis of MSC Therapy for Perianal Fistulizing and Luminal Crohn's Disease
Cao, Y., Xu, W., Sun, Y., & Jiang, Y. (2021). Efficacy and Safety of Mesenchymal Stem Cells in the Treatment of Crohn's Disease: A Systematic Review and Meta-Analysis of Clinical Trials. Stem Cell Research & Therapy, 12(1), 582. Clinical Significance: Synthesized data across 27 clinical trials evaluating local and systemic MSC administration in Crohn’s disease. Confirmed that local intralesional MSC injections yielded a pooled fistula healing rate of 64.1% with significant MRI-confirmed tract resolution. Systemic infusions produced measurable reductions in CDAI scores and corticosteroid dependence, highlighting that cellular therapies maintain a high safety index without increased incidence of serious infectious or oncologic complications.
Statutory Notice & Mandatory Regulatory Disclosure:
In compliance with the National Guidelines for Stem Cell Research jointly formulated by the Indian Council of Medical Research (ICMR) and Department of Biotechnology (DBT), as well as directives from the National Medical Commission (NMC), stem cell therapy for Crohn’s Disease is classified as strictly investigational and experimental. It is not recognized by the Central Drugs Standard Control Organisation (CDSCO) as an approved standard commercial treatment or cure. It is administered strictly within registered, ethics-committee-approved clinical research protocols. Patients are strongly advised never to stop or alter their prescribed biologics, immunomodulators, or anti-inflammatory medications without direct specialist consultation.
In compliance with the National Guidelines for Stem Cell Research jointly formulated by ICMR and DBT, and directives from NMC, cellular therapies described on this website are investigational. Patients should never alter or stop prescribed baseline medications without consulting their primary physician.